ArticlePain reports2025
Clarifying the postsurgical persistent pain after laparoscopic cholecystectomy and the role of intravenous lidocaine.
Article in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Persistent abdominal pain after laparoscopic cholecystectomy (PAPLC) incidence is estimated between 3% and 56%. Data concerning PAPLC intensity and its neuropathic characteristics is scarce, and the role of intravenous lidocaine on PAPLC is not clarified. Objectives: The authors aim to evaluate PAPLC prevalence, intensity, risk factors, and neuropathic pain (NP) characteristics. Intravenous lidocaine's impact on acute and persistent pain and opioid consumption was explored. Methods: In a 3-year follow-up, participants (n = 93) were enquired by telephone after informed consent. Sociodemographic characteristics, intraoperative and postoperative analgesia, acute pain control, preoperative chronic abdominal pain (PCAP), intensity (numeric pain scale score [NPSS]), and Results: A 15.05% prevalence of PAPLC was observed. About 57.1% of PAPLC patients reported moderate-to-severe pain. All PAPLC patients reported NP features. The intraoperative fentanyl dose ( Conclusion: This study's findings indicate a high PAPLC prevalence and a significant percentage of moderate-to-severe pain. Neuropathic pain characteristics should not be overlooked. The observed PAPLC risk factors follow the evidence. Intravenous lidocaine reduced the need for rescue opioid analgesia in the PACU and nonopioid analgesia in the postoperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.